Axial spondyloarthritis (AxSpA) encompasses a group of inflammatory arthritis conditions primarily impacting the spine, though other joints and even organs can be involved. We invite you to discover more about this range of conditions, their diagnosis and treatment options, and ways you can manage them effectively.
Living with axial spondyloarthritis (AxSpA) presents daily hurdles. There are two main types: radiographic axSpA, also known as ankylosing spondylitis, visible on X-rays due to damage to the sacroiliac joints and spine, and nonradiographic axSpA (nr-axSpA) which might not show on X-rays but can be detected through MRIs. We're here to guide you with expert advice, resources, and support to navigate through your AxSpA journey and alleviate its symptoms.
Rheumatoid arthritis (RA) is well-known for its impact on joints, causing pain, swelling, and stiffness. However, a lesser-known consequence of this autoimmune condition is the increased risk of major osteoporotic fractures. A recent study found that patients with RA are nearly 40% more likely to experience these fractures compared to individuals without RA, underscoring the importance of fracture prevention strategies in managing the disease.
RA is a chronic inflammatory condition that primarily affects the joints, but its systemic nature means that it also impacts bone health. The inflammation associated with RA can lead to bone loss, making patients more susceptible to fractures. Fragility fractures, especially in areas like the hip, spine, and wrists, are of particular concern because they can lead to long-term disability and increased mortality in older adults.
A study published in Rheumatic & Musculoskeletal Diseases Open analyzed data from the Nord-Trøndelag Health Study (HUNT) in Norway. The study included 605 patients with RA and 91,680 participants without the disease. Over the course of the study, which spanned several decades, 9,670 fractures occurred, with 88 major osteoporotic fractures recorded in the RA group. These findings highlight the significantly higher fracture risk faced by RA patients.
Disease-modifying antirheumatic drugs (DMARDs), particularly biological DMARDs (bDMARDs), are commonly used to manage inflammation in RA. These drugs help reduce joint damage and slow disease progression. However, the study sought to determine whether the use of DMARDs could also help mitigate the risk of osteoporotic fractures.
The results showed that patients with RA who were treated with bDMARDs had a slightly lower risk of fractures compared to those who were not. While the evidence was not definitive, it suggests that controlling inflammation with bDMARDs may reduce fracture risk, particularly when combined with treatments that support bone health.
“Our findings showed weak evidence that the fracture risk in bDMARDs might be comparable to participants without rheumatoid arthritis, indicating that anti-inflammatory treatment and/or antiosteoporotic treatment are important for fracture prevention in this patient group,” the study authors noted.
Fracture prevention is an essential aspect of managing rheumatoid arthritis, especially for older adults and those with long-standing disease. The increased risk of fractures in RA patients means that early intervention is crucial. Treatment strategies should include both inflammation control and bone health management.
Antiosteoporotic medications, such as bisphosphonates, can help strengthen bones and prevent fractures in individuals at high risk. Additionally, calcium and vitamin D supplementation may support bone health in patients with RA. Regular weight-bearing exercises and physical therapy can also improve bone density and muscle strength, reducing the likelihood of falls and fractures.
Beyond the physical consequences, fractures in RA patients also carry a significant economic burden. Fragility fractures often require extensive medical intervention, rehabilitation, and long-term care, placing a strain on both patients and healthcare systems. Preventing fractures through comprehensive RA management not only improves patient outcomes but also reduces healthcare costs.
The study authors concluded, “This finding may be of importance not only for individuals with rheumatoid arthritis but also for society when considering the substantial economic burden associated with fractures.”
Rheumatoid arthritis increases the risk of major osteoporotic fractures by nearly 40%, making it essential for patients and healthcare providers to focus on both joint health and bone health in managing the disease. The use of DMARDs, especially bDMARDs, may help lower fracture risk, but additional strategies such as antiosteoporotic medications, supplements, and physical therapy should be considered to reduce the likelihood of fractures.
The American Arthritis Foundation encourages individuals with RA to discuss fracture prevention with their healthcare providers. By combining inflammation control with proactive bone health strategies, patients can reduce their risk of fractures and improve their overall quality of life.
By providing my phone number, I agree to receive text messages from the business.